Fecal Microbiota-based Therapies for Select Gastrointestinal Disease
Key Points
Key Points
- Fecal microbiota-based therapies include conventional fecal microbiota transplant (FMT) and US Food and Drug Administration (FDA)-approved therapies, fecal microbiota live-jslm and fecal microbiota spores live-brpk.
- This guideline provides recommendations on the use of fecal microbiota-based therapies in adults with recurrent Clostridioides difficile infection (CDI), severe to fulminant C. difficile infection and inflammatory bowel diseases (IBDs) including pouchitis, ulcerative colitis (UC) and irritable bowel syndrome (IBS).
Treatment
Treatmen...
...ndation 1In immunocompetent adults...
...ing considerations are specific to immunocompete...
...ecommendation 2 (part 1)In mildly or moderately...
...ildly or moderately immunocompromised adults are p...
...ndation 2 (part 2)In severely immunocomprom...
...erely immunocompromised includes patien...
...ation 3In adults hospitalized with se...
...he following considerations are specific...
...dation 4In adults with ulcerative colitis,...
...Conventional FMT can reasonably be used...
...endation 5In adults with Crohn’s disea...
...e recommendation is specific to the use of conve...
...ecommendation 6In adults with pouchitis, the AGA s...
...ommendation is specific to the use of...
...mmendation 7In adults with irritable bowe...
...ndation is specific to the use of co...
...e 1. Use of Fecal Microbiota-Based Therapie...